Subscribe: Latest / All - Designed by Dr James P Howard (Google+)
GUSTO-II TRIAL |
|
|---|---|
| Problem | Suspected acute MI |
| Format | - |
| Treatment | IV heparin OR recombinant hirudin |
| Control | - |
| Population | 2564 |
| Inclusion criteria | - |
| Exclusion criteria | - |
| Follow-up | 30 days |
| Primary endpoint | Death or nonfatal MI (or reinfarction) at 30 days |
| Secondary endpoint(s) | - |
| Details | . |
| Brief summary: | |
| PAPER: Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. | |
|---|---|
| Date | 1 Oct 1994 |
| Journal | Circulation. 1994 Oct;90(4):1631-7. |
| Information | GUSTO-IIa - STOPPED EARLY DUE TO INTRACEREBRAL HAEMORRHAGIC EVENTS -Re-initiated at lower dose of hirudin (see GUSTO-IIb) Hirudin (vs. heparin) -Greater incidence of stroke --Even greater difference in those treated with thrombolysis Indication that APTT useful for predicting stroke risk in thrombolysis patients |
| PAPER: A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. | |
|---|---|
| Date | 12 Sep 1996 |
| Journal | N Engl J Med. 1996 Sep 12;335(11):775-82. |
| Information | GUSTO-IIb (Lower dose of Hirudin vs. GUSTO-IIa) Hirudin (vs. Heparin) -Significantly reduced risk of death or MI at 24hr -No significant difference at 30 days |